Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · IEX Real-Time Price · USD
1.690
+0.050 (3.05%)
Jul 22, 2024, 9:51 AM EDT - Market open
Cyclacel Pharmaceuticals Employees
Cyclacel Pharmaceuticals had 12 employees as of December 31, 2019. The number of employees decreased by 2 or -14.29% compared to the previous year.
Employees
12
Change (1Y)
-2
Growth (1Y)
-14.29%
Revenue / Employee
$37,417
Profits / Employee
-$1,653,917
Market Cap
2.47M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
FOXO Technologies | 29 |
Helius Medical Technologies | 22 |
Tenon Medical | 21 |
Catheter Precision | 14 |
InMed Pharmaceuticals | 13 |
Heart Test Laboratories | 12 |
Entero Therapeutics | 9 |
Aclarion | 6 |
CYCC News
- 26 days ago - Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions - GlobeNewsWire
- 6 weeks ago - Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 4 months ago - Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer - GlobeNewsWire
- 4 months ago - Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire